Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies

Comprehensive molecular characterization of human colon and rectal cancer

The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

OncoKB: A Precision Oncology Knowledge Base

Chakravarty, D., Gao, J., Phillips, S. M., Kundra, R., Zhang, H., Wang, J., Rudolph, J. E., Yaeger, R. D., Soumerai, T. E., Nissan, M. H., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00011 · Cited by 2,735 · see citing works

Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer

Golan, T., Hammel, P., Reni, M., Van Cutsem, E., Macarulla, T., Hall, M. J., Park, J.-O., Hochhauser, D., Arnold, D., Oh, D.-Y., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1903387 · Cited by 2,302 · see citing works

Integrated genomic characterization of oesophageal carcinoma

Sun, Q., Kelsen, D. P., Wiznerowicz, M., Lu, Y., Marra, M. A., Wan, Y., Weinhold, N., Wong, A. M., Carvalho, A. L., Luketich, J. D., et al. (2017) · Nature · doi:10.1038/nature20805 · Cited by 1,833 · see citing works

Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer

Kopetz, S., Grothey, A., Yaeger, R., Van Cutsem, E., Desai, J., Yoshino, T., Wasan, H., Ciardiello, F., Loupakis, F., Hong, Y. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1908075 · Cited by 1,491 · see citing works

Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)

Bañales, J. M., Cardinale, V., Carpino, G., Marzioni, M., Andersen, J. B., Invernizzi, P., Lind, G. E., Folseraas, T., Forbes, S. J., Fouassier, L., et al. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.51 · Cited by 1,382 · see citing works

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Abou‐Alfa, G. K., Macarulla, T. M., Javle, M. M., Kelley, R. K., Lubner, S. J., Adeva, J., Cleary, J. M., Catenacci, D. V. T., Borad, M. J., Bridgewater, J. A., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30157-1 · Cited by 1,139 · see citing works

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer

Leighl, N. B., Page, R. D., Raymond, V. M., Daniel, D. B., Divers, S. G., Reckamp, K. L., Villalona-Calero, M. A., Dix, D., Odegaard, J. I., Lanman, R. B., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0624 · Cited by 591 · see citing works

Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Parikh, A. R., Leshchiner, I., Elagina, L., Goyal, L., Levovitz, C., Siravegna, G., Livitz, D., Rhrissorrakrai, K., Martin, E. E., Van Seventer, E. E., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0561-9 · Cited by 518 · see citing works

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer

Aggarwal, C., Thompson, J. C., Black, T. A., Katz, S. I., Fan, R., Yee, S. S., Chien, A. L., Evans, T. L., Bauml, J. M., Alley, E. W., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4305 · Cited by 487 · see citing works

Multiple Roles of APC and its Therapeutic Implications in Colorectal Cancer

Zhang, L., & Shay, J. W. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw332 · Cited by 451 · see citing works

Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies

Odegaard, J. I., Vincent, J. J., Mortimer, S., Vowles, J. V., Ulrich, B. C., Banks, K. C., Fairclough, S. R., Zill, O. A., Sikora, M., Mokhtari, R. B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3831 · Cited by 437 · see citing works

A model for RAS mutation patterns in cancers: finding the sweet spot

Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384 · see citing works

Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA

Thompson, J. C., Yee, S. S., Troxel, A. B., Savitch, S. L., Fan, R., Balli, D., Lieberman, D. B., Morrissette, J. D., Evans, T. L., Bauml, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1231 · Cited by 325 · see citing works

Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer

Strickler, J. H., Loree, J. M., Ahronian, L. G., Parikh, A. R., Niedzwiecki, D., Pereira, A. A. L., McKinney, M. S., Korn, W. M., Atreya, C. E., Banks, K. C., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1009 · Cited by 296 · see citing works

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Rothwell, D. G., Ayub, M., Cook, N., Thistlethwaite, F. C., Carter, L., Dean, E. J., Smith, N., Villa, S., Dransfield, J., Clipson, A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0380-z · Cited by 290 · see citing works

Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel

Willis, J. A., Lefterova, M. I., Artyomenko, A., Kasi, P. M., Nakamura, Y., Mody, K., Catenacci, D. V. T., Fakih, M., Bárbácioru, C., Zhao, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1324 · Cited by 239 · see citing works

Circulating Tumor DNA Sequencing Analysis of Gastroesophageal Adenocarcinoma

Maron, S. B., Chase, L. M., Lomnicki, S., Kochanny, S. E., Moore, K. L., Joshi, S. S., Landron, S., Johnson, J., Kiedrowski, L. A., Nagy, R. J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1704 · Cited by 230 · see citing works

Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers

Salem, M. E., Puccini, A., Grothey, A. F., Raghavan, D., Goldberg, R. M., Xiu, J., Korn, W. M., Weinberg, B. A., Hwang, J. J., Shields, A. F., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0735 · Cited by 216 · see citing works

Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol

Meric‐Bernstam, F., Brusco, L., Daniels, M. S., Wathoo, C., Bailey, A. M., Strong, L. C., Shaw, K. R. M., Lu, K. H., Qi, Y., Zhao, H., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw018 · Cited by 196 · see citing works

Analytical Validation of the Next-Generation Sequencing Assay for a Nationwide Signal-Finding Clinical Trial

Lih, C., Harrington, R. D., Sims, D. J., Harper, K. N., Bouk, C. H., Datta, V., Yau, J., Singh, R. R., Routbort, M. J., Luthra, R., et al. (2017) · Journal of Molecular Diagnostics · doi:10.1016/j.jmoldx.2016.10.007 · Cited by 159 · see citing works

Overall Survival and Clinical Characteristics of BRCA-Associated Cholangiocarcinoma: A Multicenter Retrospective Study

Golan, T., Raitses‐Gurevich, M., Kelley, R. K., Bocobo, A. G., Borgida, A., Shroff, R. T., Holter, S., Gallinger, S., Ahn, D. H., Aderka, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0415 · Cited by 128 · see citing works

Comparative genomic analysis of esophageal squamous cell carcinoma between Asian and Caucasian patient populations

Deng, J., Chen, H., Zhou, D., Zhang, J., Chen, Y., Liu, Q., Ai, D., Zhu, H., Chu, L., Ren, W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01730-x · Cited by 119 · see citing works

Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients

Hu, Y., Alden, R. S., Odegaard, J. I., Fairclough, S. R., Chen, R., Heng, J. C., Feeney, N. B., Nagy, R. J., Shah, J. M., Ulrich, B. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1745 · Cited by 86 · see citing works

Biopsy-free circulating tumor DNA assay identifies actionable mutations in lung cancer

Villaflor, V., Won, B., Nagy, R., Banks, K., Lanman, R. B., Talasaz, A., & Salgia, R. (2016) · Oncotarget · doi:10.18632/oncotarget.11801 · Cited by 75 · see citing works

Patients with Advanced Non–Small Cell Lung Cancer: Are Research Biopsies a Barrier to Participation in Clinical Trials?

Lim, C. H., Sung, M., Shepherd, F. A., Nouriany, N., Sawczak, M., Paul, T., Perera-Low, N., Foster, A., Zawisza, D., Feld, R. D., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.09.006 · Cited by 64 · see citing works

Clinical Utility of Analyzing Circulating Tumor DNA in Patients with Metastatic Colorectal Cancer

Nakamura, Y., & Yoshino, T. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0621 · Cited by 61 · see citing works

Development of circulating tumour DNA analysis for gastrointestinal cancers

Nakamura, Y., & Shitara, K. (2020) · ESMO Open · doi:10.1136/esmoopen-2019-000600 · Cited by 33 · see citing works

The current status and problems confronted in delivering precision medicine in Japan and Europe

Bando, H. (2017) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2017.02.003 · Cited by 23 · see citing works

Non–small cell lung cancer clinical trials requiring biopsies with biomarker‐specific results for enrollment provide unique challenges

Spiegel, M. L., Goldman, J. W., Wolf, B. R., Nameth, D. J., Grogan, T., Lisberg, A. E., Wong, D. J. L., Ledezma, B. A., Mendenhall, M. A., Genshaft, S. J., et al. (2017) · Cancer · doi:10.1002/cncr.31056 · Cited by 22 · see citing works

Abstract 4272: A novel approach to differentiation of somatic vs. germline variants in liquid biopsies using a betabinomial model

Nance, T., Helman, E., Artieri, C. G., Yen, J. L., Slavin, T. P., Chudova, D. I., Lanman, R. B., & Talasaz, A. H. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-4272 · Cited by 13 · see citing works

Liquid biopsy enters the clinic — implementation issues and future challenges

Ignatiadis, M., Sledge, G. W., & Jeffrey, S. S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00457-x · Cited by 1,191 · see citing works

ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: A report from the ESMO Precision Medicine Working Group

Pascual, J., Attard, G., Bidard, F.-C., Curigliano, G., De Mattos-Arruda, L., Diehn, M., Italiano, A., Lindberg, J., Merker, J. D., Montagut, C., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.05.520 · Cited by 783 · see citing works

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment

Passaro, A., Bakir, M. A., Hamilton, E. G., Diehn, M., André, F., Roy‐Chowdhuri, S., Mountzios, G., Wistuba, I. I., Swanton, C., & Peters, S. (2024) · Cell · doi:10.1016/j.cell.2024.02.041 · Cited by 703 · see citing works

Current developments in gastric cancer: from molecular profiling to treatment strategy

Alsina, M., Arrazubi, V., Díez, M., & Tabernero, J. M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-022-00703-w · Cited by 355 · see citing works

Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices

Malla, M., Loree, J. M., Kasi, P. M., & Parikh, A. R. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.21.02615 · Cited by 305 · see citing works

Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm

Nakamura, Y., Kawazoe, A., Lordick, F., Janjigian, Y. Y., & Shitara, K. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00492-2 · Cited by 302 · see citing works

Circulating tumor DNA to monitor treatment response in solid tumors and advance precision oncology

Bartolomucci, A., de Nóbrega, M., Ferrier, S. T., Dickinson, K., Kaorey, N., Nadeau, A., Castillo, A., & Burnier, J. V. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00876-y · Cited by 287 · see citing works

Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With <i>RAS</i> Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial

Watanabe, J., Muro, K., Shitara, K., Yamazaki, K., Shiozawa, M., Ohori, H., Takashima, A., Yokota, M., Makiyama, A., Akazawa, N., et al. (2023) · JAMA · doi:10.1001/jama.2023.4428 · Cited by 280 · see citing works

Precision oncology in metastatic colorectal cancer — from biology to medicine

Nicolantonio, F. D., Vitiello, P. P., Marsoni, S., Siena, S., Tabernero, J. M., Trusolino, L., Bernards, R., & Bardelli, A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00495-z · Cited by 238 · see citing works

Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial

Nakamura, Y., Okamoto, W., Kato, T., Esaki, T., Kato, K., Komatsu, Y., Yuki, S., Masuishi, T., Nishina, T., Ebi, H., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01553-w · Cited by 231 · see citing works

The coming decade in precision oncology: six riddles

Wahida, A., Buschhorn, L., Fröhling, S., Jost, P. J., Schneeweiß, A., Lichter, P., & Kurzrock, R. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00529-3 · Cited by 214 · see citing works

Exosomes in the hypoxic TME: from release, uptake and biofunctions to clinical applications

He, G., Peng, X., Wei, S., Yang, S., Li, X., Huang, M., Tang, S., Jin, H., Liu, J., Zhang, S., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01440-5 · Cited by 201 · see citing works

Overall survival with circulating tumor DNA-guided therapy in advanced non-small-cell lung cancer

Jee, J., Lebow, E. S., Yeh, R., Das, J. P., Namakydoust, A., Paik, P. K., Chaft, J. E., Jayakumaran, G., Brannon, A. R., Benayed, R., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02047-z · Cited by 198 · see citing works

Mapping the genomic diaspora of gastric cancer

Yeoh, K. G., & Tan, P. B. O. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00412-7 · Cited by 170 · see citing works

Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives

Peng, Y., Mei, W., Ma, K., & Zeng, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.763790 · Cited by 167 · see citing works

Current and emerging therapies for advanced biliary tract cancers

Kam, A. E., Masood, A., & Shroff, R. T. (2021) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00171-0 · Cited by 167 · see citing works

CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer

Taniguchi, H., Nakamura, Y., Kotani, D., Yukami, H., Mishima, S., Sawada, K., Shirasu, H., Ebi, H., Yamanaka, T., Aleshin, A. A., et al. (2021) · Cancer Science · doi:10.1111/cas.14926 · Cited by 162 · see citing works

The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer

Berchuck, J. E., Facchinetti, F., Ditoro, D. F., Baiev, I., Majeed, U., Reyes, S., Chen, C. T., Zhang, K., Sharman, R., Usón, P. L. S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.09.150 · Cited by 152 · see citing works

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with <i>KRAS</i> G12C-Mutated Metastatic Colorectal Cancer

Yaeger, R., Uboha, N. V., Pelster, M. S., Bekaii-Saab, T. S., Barve, M., Saltzman, J., Sabari, J. K., Peguero, J. A., Paulson, A. S., Jänne, P. A., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0217 · Cited by 139 · see citing works

Practical considerations in screening for genetic alterations in cholangiocarcinoma

Bekaii‐Saab, T., Bridgewater, J. A., & Normanno, N. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.04.012 · Cited by 136 · see citing works

Recent developments in immunotherapy for gastrointestinal tract cancers

Chong, X., Madeti, Y., Cai, J., Li, W., Cong, L., Lu, J., Mo, L., Liu, H., He, S., Yu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01578-x · Cited by 129 · see citing works

Prognostic Significance of Blood-Based Multi-cancer Detection in Plasma Cell-Free DNA

Chen, X., Zhao, D., Hubbell, E. A., Kurtzman, K. N., Oxnard, G. R., Venn, O., Melton, C. A., Clarke, C. A., Shaknovich, R., Ma, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0417 · Cited by 122 · see citing works

Trastuzumab deruxtecan in HER2-positive advanced gastric cancer: exploratory biomarker analysis of the randomized, phase 2 DESTINY-Gastric01 trial

Shitara, K., Bang, Y., Iwasa, S., Sugimoto, N., Ryu, M., Sakai, D., Chung, H. C., Kawakami, H., Yabusaki, H., Sakamoto, Y., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02992-x · Cited by 115 · see citing works

Effects of Metastatic Sites on Circulating Tumor DNA in Patients With Metastatic Colorectal Cancer

Bando, H., Nakamura, Y., Taniguchi, H., Shiozawa, M., Yasui, H., Esaki, T., Kagawa, Y., Denda, T., Satoh, T., Yamazaki, K., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00535 · Cited by 111 · see citing works

A Low Tumor Mutational Burden and <i>PTEN</i> Mutations Are Predictors of a Negative Response to PD-1 Blockade in MSI-H/dMMR Gastrointestinal Tumors

Chida, K., Kawazoe, A., Kawazu, M., Suzuki, T., Nakamura, Y., Nakatsura, T., Kuwata, T., Ueno, T., Kuboki, Y., Kotani, D., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0401 · Cited by 110 · see citing works

A clinician’s handbook for using ctDNA throughout the patient journey

Hasenleithner, S. O., & Speicher, M. R. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01551-7 · Cited by 109 · see citing works

Using cfDNA and ctDNA as Oncologic Markers: A Path to Clinical Validation

Dao, J., Conway, P., Subramani, B., Meyyappan, D., Russell, S., & Mahadevan, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713219 · Cited by 107 · see citing works

Liquid biopsies to monitor and direct cancer treatment in colorectal cancer

Mauri, G., Vitiello, P. P., Sogari, A., Crisafulli, G., Bianchi, A. S., Marsoni, S., Siena, S., & Bardelli, A. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01769-8 · Cited by 105 · see citing works

Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies

Ou, X., Gao, G., Habaz, I. A., & Wang, Y. (2024) · MedComm · doi:10.1002/mco2.694 · Cited by 93 · see citing works

Gastric cancer and genomics: review of literature

Onoyama, T., Ishikawa, S., & Isomoto, H. (2022) · Journal of Gastroenterology · doi:10.1007/s00535-022-01879-3 · Cited by 82 · see citing works

Intratumor heterogeneity: the hidden barrier to immunotherapy against MSI tumors from the perspective of IFN-γ signaling and tumor-infiltrating lymphocytes

Wu, W., Liu, Y., Zeng, S., Han, Y., & Shen, H. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01166-3 · Cited by 81 · see citing works

Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors

Larribère, L., & Martens, U. M. (2021) · Cancers · doi:10.3390/cancers13225698 · Cited by 79 · see citing works

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib

Bauml, J. M., Li, B. T., Velcheti, V., Govindan, R., Fontecedro, A. C., Dooms, C., Takahashi, T., Duda, A. W., Odegaard, J. I., Cruz‐Guilloty, F., et al. (2021) · Lung Cancer · doi:10.1016/j.lungcan.2021.10.007 · Cited by 73 · see citing works

Early stage gastric adenocarcinoma: clinical and molecular landscapes

Hirata, Y., Noorani, A., Song, S., Wang, L., & Ajani, J. A. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00767-w · Cited by 73 · see citing works

Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application

Sivapalan, L., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2020) · Pancreatology · doi:10.1016/j.pan.2020.12.017 · Cited by 71 · see citing works

Acidity and hypoxia of tumor microenvironment, a positive interplay in extracellular vesicle release by tumor cells

Peppicelli, S., Calorini, L., Bianchini, F., Papucci, L., Magnelli, L., & Andreucci, E. (2024) · Cellular Oncology · doi:10.1007/s13402-024-00969-z · Cited by 70 · see citing works

How to use liquid biopsies to treat patients with cancer

Mattos‐Arruda, L. D., & Siravegna, G. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100060 · Cited by 68 · see citing works

Circulating Tumor DNA Analysis Detects FGFR2 Amplification and Concurrent Genomic Alterations Associated with FGFR Inhibitor Efficacy in Advanced Gastric Cancer

Jogo, T., Nakamura, Y., Shitara, K., Bando, H., Yasui, H., Esaki, T., Terazawa, T., Satoh, T., Shinozaki, E., Nishina, T., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1414 · Cited by 65 · see citing works

Liquid versus tissue biopsy for detecting actionable alterations according to the ESMO Scale for Clinical Actionability of molecular Targets in patients with advanced cancer: a study from the French National Center for Precision Medicine (PRISM)

Bayle, A., Peyraud, F., Belcaid, L., Brunet, M., Aldea, M. D., Clodion, R., Dubos, P., Vasseur, D., Nicotra, C., Géraud, A., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.08.089 · Cited by 65 · see citing works

Novel Biomarkers of Gastric Cancer: Current Research and Future Perspectives

Sato, Y., Okamoto, K., Kawano, Y., Kasai, A., Kawaguchi, T., Sagawa, T., Sogabe, M., Miyamoto, H., & Takayama, T. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12144646 · Cited by 64 · see citing works

Targeted therapy guided by circulating tumor DNA analysis in advanced gastrointestinal tumors

Nakamura, Y., Ozaki, H., Ueno, M., Komatsu, Y., Yuki, S., Esaki, T., Taniguchi, H., Sunakawa, Y., Yamaguchi, K., Kato, K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03244-8 · Cited by 65 · see citing works

SCRUM‐Japan GI‐SCREEN and MONSTAR‐SCREEN: Path to the realization of biomarker‐guided precision oncology in advanced solid tumors

Nakamura, Y., Fujisawa, T., Taniguchi, H., Bando, H., Okamoto, W., Tsuchihara, K., Yoshino, T., & Ohtsu, A. (2021) · Cancer Science · doi:10.1111/cas.15132 · Cited by 62 · see citing works

Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols

Cottrell, T. R., Lotze, M. T., Ali, A. M., Bifulco, C. B., Capitini, C. M., Chow, L. Q. M., Cillo, A. R., Collyar, D. E., Cope, L., Deutsch, J. S., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-010928 · Cited by 61 · see citing works

Concordance analysis of microsatellite instability status between polymerase chain reaction based testing and next generation sequencing for solid tumors

Shimozaki, K., Hayashi, H., Tanishima, S., Horie, S., Chida, A., Tsugaru, K., Togasaki, K., Kawasaki, K., Aimono, E., Hirata, K., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99364-z · Cited by 57 · see citing works

The Emerging Role of Liquid Biopsy in Gastric Cancer

Lengyel, C. G., Hussain, S., Trapani, D., Bairi, K. E., Altuna, S. C., Seeber, A., Odhiambo, A. O., Habeeb, B. S., & Seid, F. U. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102108 · Cited by 55 · see citing works

Current Status of the Diagnosis of Early-Stage Pancreatic Ductal Adenocarcinoma

Nakaoka, K., Ohno, E., Kawabe, N., Kuzuya, T., Funasaka, K., Nakagawa, Y., Nagasaka, M., Ishikawa, T., Watanabe, A., Tochio, T., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020215 · Cited by 53 · see citing works

The Role of ctDNA in Gastric Cancer

Mencel, J., Slater, S., Cartwright, E., & Starling, N. (2022) · Cancers · doi:10.3390/cancers14205105 · Cited by 51 · see citing works

Lifestyles, genetics, and future perspectives on gastric cancer in east Asian populations

Katoh, H., & Ishikawa, S. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00960-8 · Cited by 50 · see citing works

Identification and monitoring of mutations in circulating cell-free tumor DNA in hepatocellular carcinoma treated with lenvatinib

Fujii, Y., Ono, A., Hayes, C. N., Aikata, H., Yamauchi, M., Uchikawa, S., Kodama, K., Teraoka, Y., Fujino, H., Nakahara, T., et al. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02016-3 · Cited by 49 · see citing works

Early Circulating Tumor DNA Dynamics and Efficacy of Lorlatinib in Patients With Treatment-Naive, Advanced, ALK-Positive NSCLC

Soo, R. A., Martini, J.-F., van der Wekken, A. J., Teraoka, S., Ferrara, R., Shaw, A. T., Shepard, D., Calella, A. M., Polli, A., Toffalorio, F., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.05.021 · Cited by 48 · see citing works

Clinical Utility and Benefits of Comprehensive Genomic Profiling in Cancer

Tjota, M. Y., Segal, J. P., & Wang, P. (2024) · The Journal of Applied Laboratory Medicine · doi:10.1093/jalm/jfad091 · Cited by 48 · see citing works

Lutetium-177–PSMA-617 or cabazitaxel in metastatic prostate cancer: circulating tumor DNA analysis of the randomized phase 2 TheraP trial

Kwan, E. M., Ng, S. W. S., Tolmeijer, S. H., Emmett, L., Sandhu, S. K., Buteau, J. P., Iravani, A., Joshua, A. M., Francis, R. J., Subhash, V. V., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03704-9 · Cited by 47 · see citing works

Clinical dilemma of endoscopic ultrasound‐guided fine needle aspiration for resectable pancreatic body and tail cancer

Kitano, M., Minaga, K., Hatamaru, K., & Ashida, R. (2021) · Digestive Endoscopy · doi:10.1111/den.14120 · Cited by 46 · see citing works

Advances in Liquid Biopsy Technology and Implications for Pancreatic Cancer

Raufi, A. G., May, M. S., Hadfield, M. J., Seyhan, A. A., & El‐Deiry, W. S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044238 · Cited by 45 · see citing works

Impact of Preoperative Circulating Tumor DNA Status on Survival Outcomes After Hepatectomy for Resectable Colorectal Liver Metastases

Kobayashi, S., Nakamura, Y., Taniguchi, H., Odegaard, J. I., Nomura, S., Kojima, M., Sugimoto, M., Konishi, M., Gotohda, N., Takahashi, S., et al. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09449-8 · Cited by 45 · see citing works

Role of molecular genetics in the clinical management of cholangiocarcinoma

Normanno, N., Martinelli, E., Melisi, D., Pinto, C., Rimassa, L., Santini, D., & Scarpa, A. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100505 · Cited by 44 · see citing works

The initial assessment of expert panel performance in core hospitals for cancer genomic medicine in Japan

Sunami, K., Naito, Y., Aimono, E., Amano, T., Ennishi, D., Kage, H., Kanai, M., Komine, K., Koyama, T., Maeda, T., et al. (2021) · International Journal of Clinical Oncology · doi:10.1007/s10147-020-01844-1 · Cited by 44 · see citing works

Comprehensive genomic profiling for oncological advancements by precision medicine

Pankiw, M., Brezden‐Masley, C., & Charames, G. S. (2023) · Medical Oncology · doi:10.1007/s12032-023-02228-x · Cited by 43 · see citing works

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial

Yagisawa, M., Taniguchi, H., Satoh, T., Kadowaki, S., Sunakawa, Y., Nishina, T., Komatsu, Y., Esaki, T., Sakai, D., Doi, A., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02626 · Cited by 43 · see citing works

Progress on diagnostic and prognostic markers of pancreatic cancer

YANG, H., Li, W., Ren, L., Yang, Y., Zhang, Y., Ge, B., Li, S., Zheng, X., Liu, J., Zhang, S., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028905 · Cited by 42 · see citing works

Circulating Tumor DNA-Based Genomic Profiling Assays in Adult Solid Tumors for Precision Oncology: Recent Advancements and Future Challenges

Chan, H. T., Chin, Y. M., & Low, S. (2022) · Cancers · doi:10.3390/cancers14133275 · Cited by 41 · see citing works

Circulating Tumor DNA to Drive Treatment in Metastatic Colorectal Cancer

Patelli, G., Mauri, G., Tosi, F., Amatu, A., Bencardino, K. B., Bonazzina, E. F., Pizzutilo, E. G., Villa, F., Calvanese, G., Agostara, A. G., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0079 · Cited by 41 · see citing works

Molecular Targets for Gastric Cancer Treatment and Future Perspectives from a Clinical and Translational Point of View

Körfer, J., Lordick, F., & Hacker, U. T. (2021) · Cancers · doi:10.3390/cancers13205216 · Cited by 41 · see citing works

Liquid biopsy versus tumor biopsy for clinical-trial recruitment

Corcoran, R. B. (2020) · Nature Medicine · doi:10.1038/s41591-020-01169-6 · Cited by 41 · see citing works

Use of Circulating Tumour DNA (ctDNA) for Measurement of Therapy Predictive Biomarkers in Patients with Cancer

Duffy, M. J., & Crown, J. P. (2022) · Journal of Personalized Medicine · doi:10.3390/jpm12010099 · Cited by 40 · see citing works

Extracellular vesicle-cell adhesion molecules in tumours: biofunctions and clinical applications

Lin, W., Fang, J., Wei, S., He, G., Liu, J., Li, X., Peng, X., Dai, L., Yang, S., Li, X., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01236-8 · Cited by 37 · see citing works

Clinical implementation and current advancement of blood liquid biopsy in cancer

Watanabe, K., Nakamura, Y., & Low, S. (2021) · Journal of Human Genetics · doi:10.1038/s10038-021-00939-5 · Cited by 37 · see citing works

Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as a Liquid Biopsy Marker in Colorectal Cancer

Heidrich, I., Abdalla, T. S. A., Reeh, M., & Pantel, K. (2021) · Cancers · doi:10.3390/cancers13184500 · Cited by 38 · see citing works

Cell-free DNA testing for early hepatocellular carcinoma surveillance

Chen, L., Wu, T., Fan, R., Qian, Y.-S., Liu, J., Bai, J., Zheng, B. J., Liu, X., Zheng, D., Du, L., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2023.104962 · Cited by 36 · see citing works

Establishment of an Immune Cell Infiltration Score to Help Predict the Prognosis and Chemotherapy Responsiveness of Gastric Cancer Patients

Jiang, Q., Sun, J., Chen, H., Ding, C., Tang, Z., Ruan, Y., Liu, F., & Sun, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.650673 · Cited by 36 · see citing works

Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy

Carotenuto, M., Sacco, A., Forgione, L., & Normanno, N. (2022) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2022.00079 · Cited by 35 · see citing works

Clinical significance of circulating-tumour DNA analysis by metastatic sites in pancreatic cancer

Umemoto, K., Sunakawa, Y., Ueno, M., Furukawa, M., Mizuno, N., Sudo, K., Kawamoto, Y., Kajiwara, T., Ohtsubo, K., Okano, N., et al. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02189-y · Cited by 34 · see citing works

Development of a molecular barcode detection system for pancreaticobiliary malignancies and comparison with next-generation sequencing

Ohyama, H., Hirotsu, Y., Amemiya, K., Mikata, R., Amano, H., Hirose, S., Oyama, T., Iimuro, Y., Kojima, Y., Mochizuki, H., et al. (2023) · Cancer Genetics · doi:10.1016/j.cancergen.2023.12.002 · Cited by 34 · see citing works

Molecular profiling and treatment pattern differences between intrahepatic and extrahepatic cholangiocarcinoma

Spencer, K. R., Pappas, L., Baiev, I., Maurer, J. R., Bocobo, A. G., Zhang, K., Jain, A., Armas, A. D. D., Reyes, S., Le, T. M., et al. (2023) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djad046 · Cited by 33 · see citing works

Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance

Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32 · see citing works

Whole-exome tumor-agnostic ctDNA analysis enhances minimal residual disease detection and reveals relapse mechanisms in localized colon cancer

Martín-Arana, J., Gimeno-Valiente, F., Henriksen, T. V., García-Micó, B., Martínez-Castedo, B., Gambardella, V., Martínez‐Ciarpaglini, C., Lucas, B. P.-D., Huerta, M., Camblor, D. G., et al. (2025) · Nature Cancer · doi:10.1038/s43018-025-00960-z · Cited by 32 · see citing works

The Essentials of Multiomics

Marshall, J. L., Peshkin, B. N., Yoshino, T., Vowinckel, J., Danielsen, H. E., Melino, G., Tsamardinos, I., Haudenschild, C. D., Kerr, D. J., Sampaio, C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyab048 · Cited by 32 · see citing works

Circulating Tumor DNA: A Pan-Cancer Biomarker in Solid Tumors with Prognostic and Predictive Value

Hitchen, N., Shahnam, A., & Tie, J. (2024) · Annual Review of Medicine · doi:10.1146/annurev-med-100223-090016 · Cited by 31 · see citing works

Applications of Liquid Biopsy for Surgical Patients With Cancer

Mahuron, K. M., & Fong, Y. (2023) · JAMA Surgery · doi:10.1001/jamasurg.2023.5394 · Cited by 30 · see citing works

Clinical Validity of Plasma-Based Genotyping for Microsatellite Instability Assessment in Advanced GI Cancers: SCRUM-Japan GOZILA Substudy

Nakamura, Y., Okamoto, W., Denda, T., Nishina, T., Komatsu, Y., Yuki, S., Yasui, H., Esaki, T., Sunakawa, Y., Ueno, M., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00383 · Cited by 30 · see citing works

Implementing the European Society for Medical Oncology Scale for Clinical Actionability of Molecular Targets in a Comprehensive Profiling Program: Impact on Precision Medicine Oncology

Martín-Romano, P., Mezquita, L., Hollebecque, A., Lacroix, L., Rouleau, É., Gazzah, A., Bahleda, R., Planchard, D., Varga, A., Baldini, C., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00484 · Cited by 30 · see citing works

The biological function of tumor-derived extracellular vesicles on metabolism

Fu, X., Song, J., Yan, W., Downs, B. M., Wang, W., & Li, J. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01111-6 · Cited by 30 · see citing works

Targeted Therapies and Developing Precision Medicine in Gastric Cancer

Pihlak, R., Fong, C., & Starling, N. (2023) · Cancers · doi:10.3390/cancers15123248 · Cited by 29 · see citing works

TP53 and/or BRCA1 Mutations Based on CtDNA Analysis as Prognostic Biomarkers for Primary Triple-Negative Breast Cancer

Arimura, A., Sakai, K., Kaneshiro, K., Morisaki, T., Hayashi, S., Mizoguchi, K., Yamada, M., Kai, M., Ono, M., Nishio, K., et al. (2024) · Cancers · doi:10.3390/cancers16061184 · Cited by 28 · see citing works

Molecular and Phenotypic Profiling for Precision Medicine in Pancreatic Cancer: Current Advances and Future Perspectives

Miyabayashi, K., Nakagawa, H., & Koike, K. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682872 · Cited by 28 · see citing works

Next-Generation Sequencing on Circulating Tumor DNA in Advanced Solid Cancer: Swiss Army Knife for the Molecular Tumor Board? A Review of the Literature Focused on FDA Approved Test

Vasseur, D., Sassi, H., Bayle, A., Tagliamento, M., Besse, B., Marzac, C., Arbab, A., Auger, N., Cotteret, S., Aldea, M. D., et al. (2022) · Cells · doi:10.3390/cells11121901 · Cited by 28 · see citing works

Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma

Ooki, A., Osumi, H., Chìn, K., Watanabe, M., & Yamaguchi, K. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359221138377 · Cited by 28 · see citing works

Cooperation and Interplay between EGFR Signalling and Extracellular Vesicle Biogenesis in Cancer

Zanetti-Domingues, L. C., Bonner, S. E., Iyer, R. S., Martin-Fernandez, M. L., & Huber, V. (2020) · Cells · doi:10.3390/cells9122639 · Cited by 28 · see citing works

Addressing Challenges in Targeted Therapy for Metastatic Colorectal Cancer

Hage, M. E., Su, Z., & Linnebacher, M. (2025) · Cancers · doi:10.3390/cancers17071098 · Cited by 27 · see citing works

Validity and utility of blood tumor mutational burden (bTMB) is dependent on circulating tumor DNA (ctDNA) shed: SCRUM-Japan MONSTAR-SCREEN

Mishima, S., Nakamura, Y., Tukachinsky, H., Taniguchi, H., Kadowaki, S., Kato, K., Oki, E., Satoh, T., Aoki, D., Yamazaki, K., et al. (2023) · The Journal of Liquid Biopsy · doi:10.1016/j.jlb.2023.100003 · Cited by 27 · see citing works

Circulating Tumor DNA detection in cancer: a comprehensive overview of current detection methods and prospects

de Abreu, A. R., Wyninckx, A., Vandamme, T., de Beeck, K. O., Camp, G. V., Peeters, M., Laurent‐Puig, P., Taı̈eb, J., Taly, V., & Benhaïm, L. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf204 · Cited by 26 · see citing works

Longitudinal profiling of circulating tumour DNA for tracking tumour dynamics in pancreatic cancer

Sivapalan, L., Thorn, G. J., Gadaleta, E., Kocher, H. M., Ross‐Adams, H., & Chelala, C. (2022) · BMC Cancer · doi:10.1186/s12885-022-09387-6 · Cited by 26 · see citing works

Challenges and Obstacles in Applying Therapeutical Indications Formulated in Molecular Tumor Boards

Crimini, E., Repetto, M., Tarantino, P., Ascione, L., Antonarelli, G., Guerini‐Rocco, E., Barberis, M. C. P., Mazzarella, L., & Curigliano, G. (2022) · Cancers · doi:10.3390/cancers14133193 · Cited by 26 · see citing works

Appropriate use of cancer comprehensive genome profiling assay using circulating tumor DNA

Sunami, K., Bando, H., Yatabe, Y., Naito, Y., Takahashi, H. E., Tsuchihara, K., Toyooka, S., Mimori, K., Kohsaka, S., Uetake, H., et al. (2021) · Cancer Science · doi:10.1111/cas.15022 · Cited by 24 · see citing works

Implementation of a Molecular Tumor Registry to Support the Adoption of Precision Oncology Within an Academic Medical Center: The Duke University Experience

Green, M. F., Bell, J. L., Hubbard, C. B., McCall, S. J., McKinney, M. S., Riedel, J., Menendez, C. S., Abbruzzese, J. L., Strickler, J. H., & Datto, M. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00030 · Cited by 24 · see citing works

Clinical applications and perspectives of circulating tumor DNA in gastric cancer

Li, J. M., Zhang, D., Zhu, J., & Dong, L. (2024) · Cancer Cell International · doi:10.1186/s12935-024-03209-4 · Cited by 24 · see citing works

Liquid biopsy for gastric cancer: Techniques, applications, and future directions

del Arco, C. D., Fernández‐Aceñero, M. J., & Medina, L. O. (2024) · World Journal of Gastroenterology · doi:10.3748/wjg.v30.i12.1680 · Cited by 23 · see citing works

Rapid Screening Using Pathomorphologic Interpretation to Detect BRAF V600E Mutation and Microsatellite Instability in Colorectal Cancer

Fujii, S., Kotani, D., Hattori, M., Nishihara, M., Shikanai, T., Hashimoto, J., Hama, Y., Nishino, T., Suzuki, M., Yoshidumi, A., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-4391 · Cited by 22 · see citing works

Endoscopic ultrasound‐guided tissue acquisition for pancreatic ductal adenocarcinoma in the era of precision medicine

Ashida, R., & Kitano, M. (2022) · Digestive Endoscopy · doi:10.1111/den.14344 · Cited by 22 · see citing works

Essential updates 2020/2021: Advancing precision medicine for comprehensive rectal cancer treatment

Takemasa, I., Hamabe, A., Miyo, M., Akizuki, E., & Okuya, K. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12646 · Cited by 22 · see citing works

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (Pts) with advanced gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA Combined Analysis.

Nakamura, Y., Taniguchi, H., Bando, H., Kato, K., Esaki, T., Komatsu, Y., Takahashi, N., Ueno, M., Kagawa, Y., Nishina, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.4_suppl.5 · Cited by 4 · see citing works

Utility of circulating tumor DNA (ctDNA) versus tumor tissue clinical sequencing for enrolling patients (pts) with advanced non-colorectal (non-CRC) gastrointestinal (GI) cancer to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.

Ohba, A., Nakamura, Y., Taniguchi, H., Ikeda, M., Bando, H., Mizuno, N., Kato, K., Morizane, C., Nishina, T., Ueno, M., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.3516 · Cited by 3 · see citing works

Utility of circulating tumor DNA (ctDNA) versus tumor tissue genotyping for enrollment of patients with metastatic colorectal cancer (mCRC) to matched clinical trials: SCRUM-Japan GI-SCREEN and GOZILA combined analysis.

Nakamura, Y., Taniguchi, H., Bando, H., Esaki, T., Komatsu, Y., Kato, K., Takahashi, N., Kagawa, Y., Kato, T., Nishina, T., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.4071

[Clinical Utility of Circulating Tumor DNA Analysis for Precision Medicine in Patients with Advanced Gastrointestinal Cancer].

Nakamura, Y. (2021) · PubMed

JS01-4 Liquid biopsy-guided precision oncology in advanced solid tumors

Nakamura, Y. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.09.023